Clas Malmeström
-
Presence of neural surface and onconeural autoantibodies in cerebrospinal fluid and serum in neurological diseases presents a potential risk for
misdiagnosis
Oskar Stevens-Jones, Clas Malmeström, Clara Constantinescu, Keti Dalla, Bengt Nellgård, Johan Zelano, Radu Constantinescu, Markus Axelsson
European Journal of Neurology - 2023 -
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple
sclerosis
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Clas Malmeström, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Journal of Neurology - 2023 -
The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective
survey
Sofia Sandgren, Lenka Novakova, Markus Axelsson, Firoozeh Amirbeagi, I. Kockum, T. Olsson, Clas Malmeström, Jan Lycke
Frontiers in Neurology - 2023 -
SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated
disorder
Magnus Johnsson, Fredrik Asztely, S. Hejnebo, Markus Axelsson, Clas Malmeström, T. Olausson, Jan Lycke
Annals of Clinical and Translational Neurology - 2022 -
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of
natalizumab
Magnus Johnsson, Helen H. Farman, Kaj Blennow, Henrik Zetterberg, Clas Malmeström, Markus Axelsson, Jan Lycke
Multiple Sclerosis Journal - 2022 -
Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of
life
Clara Constantinescu, Lenka Novakova, Clas Malmeström, Radu Constantinescu, Markus Axelsson, Jan Lycke
Multiple Sclerosis and Related Disorders - 2021 -
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: An observational
study
Christina Zhukovsky, Sofia Sandgren, Thomas Silfverberg, Sigrun Einarsdottir, Andreas Tolf, Anne Marie Landtblom, Lenka Novakova, Markus Axelsson, Clas Malmeström, Honar Cherif, Kristina Carlson, Jan Lycke, Joachim Burman
Journal of Neurology, Neurosurgery and Psychiatry - 2021 -
Inflammation-related plasma and CSF biomarkers for multiple
sclerosis
J. Huang, M. Khademi, L. Fugger, O. Lindhe, Lenka Novakova, Markus Axelsson, Clas Malmeström, Clara Constantinescu, Jan Lycke, F. Piehl, T. Olsson, I. Kockum
Proceedings of the National Academy of Sciences of the United States of America - 2020 -
NFL and CXCL13 may reveal disease activity in clinically and radiologically stable
MS
Lenka Novakova, M Axelsson, Clas Malmeström, Henrik Zetterberg, Kaj Blennow, A. Svenningsson, Jan Lycke
Multiple Sclerosis and Related Disorders - 2020 -
Intrathecal immunoreactivity in people with or without previous infectious
mononucleosis.
Daniel Jons, Henrik Zetterberg, Clas Malmeström, Tomas Bergström, Markus Axelsson, Kaj Blennow, Måns Thulin, Peter Sundström, Oluf Andersen
Acta neurologica Scandinavica - 2020 -
Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular
Identifiers.
Gustav Johansson, Melita Kaltak, Cristiana Rîmniceanu, Avadhesh Kumar Singh, Jan Lycke, Clas Malmeström, Michael Hühn, Outi Vaarala, Susanna Cardell, Anders Ståhlberg
Clinical chemistry - 2020 -
Cerebrospinal fluid CD4(+)/CD8(+)ratio in diagnosing
neurosarcoidosis
Sara Nordström, Bengt Andersson, Clas Malmeström
Acta Neurologica Scandinavica - 2020 -
Cerebrospinal fluid growth-associated protein 43 in multiple
sclerosis.
Åsa P Sandelius, Sofia Sandgren, Markus Axelsson, Clas Malmeström, Lenka Novakova, Vesna Kostanjevecki, Manu Vandijck, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Scientific reports - 2019 -
Neuronal antibodies in adult patients with new-onset seizures: A prospective
study
Johan Zelano, Markus Axelsson, Radu Constantinescu, Clas Malmeström, E. Kumlien
Brain and Behavior - 2019 -
CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type
1
Pontus Wasling, Clas Malmeström, Kaj Blennow
Neurology, neuroimmunology & neuroinflammation - 2019 -
Cerebrospinal fluid NCAM levels are modulated by disease-modifying
therapies
Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni, Jan Lycke, S. Gnanapavan
Acta Neurologica Scandinavica - 2019 -
Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting
MS
Lenka Novakova, Avadhesh Kumar Singh, Markus Axelsson, Marcus Ståhlman, Martin Adiels, Clas Malmeström, Henrik Zetterberg, Jan Borén, Jan Lycke, Susanna Cardell, Maria K. Blomqvist
Journal of Neurochemistry - 2018 -
Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of
biomarkers.
Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Imberg, Henrik Zetterberg, Olle Nerman, Jan Lycke
PloS one - 2018 -
Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying
malignancies.
Radu Constantinescu, Fredrik Asztély, Filip Bergquist, Henrik Zetterberg, Ulf Andreasson, Markus Axelsson, Elinor Ben-Menachem, Daniel Jons, Clas Malmeström, Lars Rosengren, Kaj Blennow
Journal of neuroimmunology - 2017 -
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple
sclerosis.
Lenka Novakova, Markus Axelsson, Mohsen Khademi, Henrik Zetterberg, Kaj Blennow, Clas Malmeström, Fredrik Piehl, Thomas Olsson, Jan Lycke
Multiple sclerosis (Houndmills, Basingstoke, England) - 2017 -
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple
sclerosis.
Lenka Nováková Nyrén, Markus Axelsson, Mohsen Khademi, Henrik Zetterberg, Kaj Blennow, Clas Malmeström, Fredrik Piehl, Tomas Olsson, Jan Lycke
Journal of neurochemistry - 2017 -
Monitoring disease activity in multiple sclerosis using serum neurofilament light
protein.
Lenka Novakova, Henrik Zetterberg, Peter Sundström, Markus Axelsson, Martin Gunnarsson, Clas Malmeström, Fredrik Piehl, Kaj Blennow, Jan Lycke
Neurology - 2017 -
High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple
Sclerosis.
Avadhesh Kumar Singh, Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke, Susanna Cardell
Frontiers in Immunology - 2017 -
An observational study of alemtuzumab following fingolimod for multiple
sclerosis
M. Willis, O. Pearson, Z. Illes, T. Sejbaek, C. Nielsen, M. Duddy, K. Petheram, C. van Munster, J. Killestein, Clas Malmeström, E. Tallantyre, N. Robertson
Neurology-Neuroimmunology & Neuroinflammation - 2017 -
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or
mitoxantrone.
Annika Öhrfelt, Markus Axelsson, Clas Malmeström, Lenka Novakova, Amanda Heslegrave, Kaj Blennow, Jan Lycke, Henrik Zetterberg
Multiple sclerosis (Houndmills, Basingstoke, England) - 2016 -
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple
sclerosis.
Joachim Burman, Raili Raininko, Kaj Blennow, Henrik Zetterberg, Markus Axelsson, Clas Malmeström
Journal of neuroimmunology - 2016 -
Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune
encephalitis
Radu Constantinescu, David Krysl, Filip Bergquist, Kerstin Andrén, Clas Malmeström, Fredrik Asztely, Markus Axelsson, Elinor Ben-Menachem, Kaj Blennow, Lars Rosengren, Henrik Zetterberg
European Journal of Neurology - 2016 -
Rituximab in multiple
sclerosis
J. Salzer, R. Svenningsson, P. Alping, Lenka Novakova, A. Björck, K. Fink, P. Islam-Jakobsson, Clas Malmeström, Markus Axelsson, M. Vågberg, P. Sundström, Jan Lycke, F. Piehl, A. Svenningsson
Neurology - 2016 -
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis
Patients
P. Alping, T. Frisell, Lenka Novakova, P. Islam-Jakobsson, J. Salzer, A. Bjorck, Markus Axelsson, Clas Malmeström, K. Fink, Jan Lycke, A. Svenningsson, F. Piehl
Annals of Neurology - 2016 -
Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple
Sclerosis
Maria Kneider, Vera Lisovskaja, Jan Lycke, Clas Malmeström, Johannes Jakobsen, Olle Nerman, Oluf Andersen
Neuroepidemiology - 2015 -
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple
sclerosis.
Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Ingemar Björkhem, Virginija Danylaité Karrenbauer, Jan Lycke
Journal of the Neurological Sciences - 2015 -
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre
study
J. Kuhle, G. Disanto, R. Dobson, R. Adiutori, L. Bianchi, J. Topping, J. P. Bestwick, U. C. Meier, M. Marta, G. Dalla Costa, T. Runia, E. Evdoshenko, N. Lazareva, E. Thouvenot, P. Iaffaldano, V. Direnzo, M. Khademi, F. Piehl, M. Comabella, M. Sombekke, J. Killestein, H. Hegen, S. Rauch, S. D'Alfonso, J. C. Alvarez-Cermeno, P. Kleinova, D. Horakova, R. Roesler, F. Lauda, S. Llufriu, T. Avsar, U. Uygunoglu, A. Altintas, S. Saip, T. Menge, C. Rajda, R. Bergamaschi, N. Moll, M. Khalil, R. Marignier, I. Dujmovic, H. Larsson, Clas Malmeström, E. Scarpini, C. Fenoglio, S. Wergeland, A. Laroni, V. Annibali, S. Romano, A. D. Martinez, A. Carra, M. Salvetti, A. Uccelli, O. Torkildsen, K. M. Myhr, D. Galimberti, K. Rejdak, Jan Lycke, J. L. Frederiksen, J. Drulovic, C. Confavreux, D. Brassat, C. Enzinger, S. Fuchs, I. Bosca, J. Pelletier, C. Picard, E. Colombo, D. Franciotta, T. Derfuss, R. L. P. Lindberg, O. Yaldizli, L. Vecsei, B. C. Kieseier, H. P. Hartung, P. Villoslada, A. Siva, A. Saiz, H. Tumani, E. Havrdova, L. M. Villar, M. Leone, N. Barizzone, F. Deisenhammer, C. Teunissen, X. Montalban, M. Tintore, T. Olsson, M. Trojano, S. Lehmann, G. Castelnovo, S. Lapin, R. Hintzen, L. Kappos, R. Furlan, V. Martinelli, G. Comi, S. V. Ramagopalan, G. Giovannoni
Multiple Sclerosis Journal - 2015 -
Immunosuppressive therapy reduces axonal damage in progressive multiple
sclerosis.
Markus Axelsson, Clas Malmeström, Martin Gunnarsson, Henrik Zetterberg, Peter Sundström, Jan Lycke, Anders Svenningsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2014 -
First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in
MS.
Clas Malmeström, Bengt A. Andersson, Jan Lycke
Journal of neurology - 2014 -
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive
treatment.
Clas Malmeström, Markus Axelsson, Jan Lycke, Henrik Zetterberg, Kaj Blennow, Bob Olsson
Journal of neuroimmunology - 2014 -
MS risk genes are transcriptionally regulated in CSF leukocytes at
relapse
Margareta Jernås, Clas Malmeström, Markus Axelsson, Caroline Olsson, Intawat Nookaew, Hans Wadenvik, Henrik Zetterberg, Kaj Blennow, Jan Lycke, Mats Rudemo, Bob Olsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2013 -
The impact of rituximab therapy in multiple sclerosis on cerebrospinal fluid cell gene
expression
Margareta Jernås, Clas Malmeström, Intawat Nookaew, Hans Wadenvik, Bob Olsson, Jan Lycke
Multiple Sclerosis Journal: 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS - 2013 -
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple
sclerosis.
Markus Axelsson, Niklas Mattsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
Journal of Neuroimmunology - 2013 -
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple
sclerosis
J Kuhle, Clas Malmeström, Markus Axelsson, K Plattner, O Yaldizli, T Derfuss, G Giovannoni, L Kappos, Jan Lycke
Acta neurologica Scandinavica - 2013 -
Serum levels of LIGHT in
MS
Clas Malmeström, Alan Gillett, Margareta Jernås, Mohsen Khademi, Markus Axelsson, Ingrid Kockum, Niklas Mattsson, Henrik Zetterberg, Kaj Blennow, Lars Alfredsson, Hans Wadenvik, Jan Lycke, Tomas Olsson, Bob Olsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2013 -
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating
drugs.
Helen Tedeholm, Jan Lycke, Bengt Skoog, Vera Lisovskaja, J Hillert, C Dahle, J Fagius, S Fredrikson, A-M Landtblom, Clas Malmeström, C Martin, F Piehl, Björn Runmarker, L Stawiarz, M Vrethem, Olle Nerman, Oluf Andersen
Multiple Sclerosis Journal - 2013 -
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple
sclerosis.
Kristin Augutis, Markus Axelsson, Erik Portelius, Gunnar Brinkmalm, Ulf Andreasson, Mikael K Gustavsson, Clas Malmeström, Jan Lycke, Kaj Blennow, Henrik Zetterberg, Niklas Mattsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2013 -
MicroRNA regulate immune pathways in T-cells in multiple sclerosis
(MS)
Margareta Jernås, Clas Malmeström, Markus Axelsson, Intawat Nookaew, Hans Wadenvik, Jan Lycke, Bob Olsson
BMC Immunology - 2013 -
Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical
Trials
Bob Olsson, Clas Malmeström, H. Basun, P. Annas, Kina Höglund, L. Lannfelt, N. Andreasen, Henrik Zetterberg, Kaj Blennow
Journal of Alzheimers Disease - 2012 -
Glial fibrillary acidic protein: a potential biomarker for progression in multiple
sclerosis.
M Axelsson, Clas Malmeström, Staffan Nilsson, Sara Haghighi, Lars Rosengren, Jan Lycke
Journal of neurology - 2011 -
reply to Letter to the Editor "The neurofilament light chain is not stable in
vitro"
M Gunnarsson, Clas Malmeström, Lars Rosengren, Jan Lycke, A Svenningsson
Annals of Neurol - 2011 -
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4
trial.
Per Soelberg Sorensen, Jan Lycke, Juha-Pekka Erälinna, Astrid Edland, Xingchen Wu, Jette Lautrup Frederiksen, Annette Oturai, Clas Malmeström, Egon Stenager, Finn Sellebjerg, Helle Bach Sondergaard, investigators study for the SIMCOMBIN
Lancet neurology - 2011 -
Axonal damage in relapsing multiple sclerosis is markedly reduced by
natalizumab.
Martin Gunnarsson, Clas Malmeström, Markus Axelsson, Peter Sundström, Charlotte Dahle, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, Niklas Norgren, Lars Rosengren, Anders Svenningsson, Jan Lycke
Annals of neurology - 2011 -
Processing in prefrontal cortex underlies tactile direction discrimination: An fMRI study of a patient with a traumatic spinal cord
lesion.
Linda Lundblad, Håkan Olausson, Clas Malmeström, Helena Backlund Wasling
Neuroscience letters - 2010 -
[Neuromyelitis optica--important differential diagnosis to MS. Early treatment initiation crucial for the
prognosis].
Jan Lycke, Clas Malmeström
Läkartidningen - 2010 -
Reduced cerebrospinal fluid BACE1 activity in multiple
sclerosis.
Niklas Mattsson, M Axelsson, Sara Haghighi, Clas Malmeström, G Wu, Rolf Anckarsäter, S Sankaranarayanan, Ulf Andreasson, S Fredrikson, A Gundersen, L Johnsen, T Fladby, Andrej Tarkowski, E Trysberg, Anders Wallin, Henrik Anckarsäter, Jan Lycke, Oluf Andersen, A J Simon, Kaj Blennow, Henrik Zetterberg
Multiple sclerosis (Houndmills, Basingstoke, England) - 2009 -
Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in
CSF.
Clas Malmeström, Jan Lycke, Sara Haghighi, Oluf Andersen, Lena M S Carlsson, Hans Wadenvik, Bob Olsson
Journal of neuroimmunology - 2008 -
Blood and CSF biomarkers for investigation of the immunopathogenesis of relapse in Multiple
Sclerosis
Clas Malmeström
2008 -
IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: Implications for their possible immunopathogenic
roles
Clas Malmeström, Bengt A. Andersson, Sara Haghighi, Jan Lycke
Journal of Neuroimmunology - 2006